Eligard and Ibrance drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Eligard (leuprolide acetate) and Ibrance (palbociclib). Common drug interactions include fatigue among females and haemoglobin decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Eligard and Ibrance. It is created by eHealthMe based on reports of 35 people who take the same drugs from the FDA, and is updated regularly.

What is Eligard?

Eligard has active ingredients of leuprolide acetate. It is often used in prostate cancer. eHealthMe is studying from 44,652 Eligard users. Check the latest studies of Eligard.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,434 Ibrance users. Check the latest studies of Ibrance.

On Jul, 07, 2026

35 people who take Eligard and Ibrance together, and have interactions are studied.

What are the common drug interactions of Eligard and Ibrance, by gender? *:

female:

Fatigue (feeling of tiredness)
White blood cell count decreased
Superior vena cava syndrome (obstruction of blood flow through the superior vena cava)
Breast cancer metastatic
Arthralgia (joint pain)
Dyspnoea (difficult or laboured respiration)
Anaemia (lack of blood)
Constipation
Diarrhoea
Insomnia (sleeplessness)

male:

Haemoglobin decreased
Neutropenia (an abnormally low number of neutrophils)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Platelet count decreased
Thrombocytopenia (decrease of platelets in blood)
White blood cell count decreased
Bone marrow failure
Myelosuppression (a decrease in the production of blood cells)
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)

What are the common drug interactions of Eligard and Ibrance, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Fatigue (feeling of tiredness)
Ascites (accumulation of fluid in the abdominal cavity)
Cardiac failure congestive
Drug-induced liver injury (diseases of the liver that are caused by physician-prescribed medications)
Dyspnoea (difficult or laboured respiration)
Malaise (a feeling of general discomfort or uneasiness)
Nausea (feeling of having an urge to vomit)
Pericardial effusion (fluid around the heart)
Pleural effusion (water on the lungs)
Vomiting

40-49:

White blood cell count decreased
Fatigue (feeling of tiredness)
Anaemia (lack of blood)
Constipation
Insomnia (sleeplessness)
Neutropenia (an abnormally low number of neutrophils)
Night sweats (sweating in night)
Full blood count decreased
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Arthralgia (joint pain)

50-59:

Dyspepsia (indigestion)
Dyspnoea (difficult or laboured respiration)
Myalgia (muscle pain)
Neoplasm progression (growth of tumour)
Death
Superior vena cava syndrome (obstruction of blood flow through the superior vena cava)
Breast cancer metastatic
Arthralgia (joint pain)
Diarrhoea
Joint stiffness

60+:

Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Neoplasm progression (growth of tumour)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)

What are the existing conditions these people have? *

Breast Cancer Metastatic: 16 people, 45.71%
Metastases To Bone (cancer spreads to bone): 6 people, 17.14%
Breast Cancer Female: 4 people, 11.43%
Breast Neoplasm (non cancerous tumour of breast): 3 people, 8.57%
Breast Cancer: 2 people, 5.71%

* Approximation only. Some reports may have incomplete information.

Do you take Eligard and Ibrance?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously